These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24070900)

  • 1. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
    Iacovelli R; Alesini D; Palazzo A; Trenta P; Santoni M; De Marchis L; Cascinu S; Naso G; Cortesi E
    Cancer Treat Rev; 2014 Mar; 40(2):271-5. PubMed ID: 24070900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
    Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
    Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
    BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of first-line therapy for metastatic renal cell carcinoma.
    Porta C; Szczylik C
    Cancer Treat Rev; 2009 May; 35(3):297-307. PubMed ID: 19249157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
    Heng DY; Choueiri TK; Rini BI; Lee J; Yuasa T; Pal SK; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie M; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Wood LA
    Ann Oncol; 2014 Jan; 25(1):149-54. PubMed ID: 24356626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
    Hess G; Borker R; Fonseca E
    Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
    BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
    Joly F
    Bull Cancer; 2011 Oct; 98(9):1071-81. PubMed ID: 21914577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
    Liu F; Chen X; Peng E; Guan W; Li Y; Hu Z; Ye Z; Zhuang Q
    J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):799-806. PubMed ID: 22173502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    Chowdhury S; Larkin JM; Gore ME
    Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.